{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:08:18Z","timestamp":1790212098306,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["OPP1112700"],"award-info":[{"award-number":["OPP1112700"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115251","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:41:22Z","timestamp":1786376482000},"page":"115251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigating the weak antibody response to vaccination with inactivated polio virus serotype 3 when delivered by microneedle patch"],"prefix":"10.1016","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4643-4360","authenticated-orcid":false,"given":"Yasmine","family":"Gomaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-5490","authenticated-orcid":false,"given":"Chandana","family":"Kolluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-5641","authenticated-orcid":false,"given":"Jeong Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-8448","authenticated-orcid":false,"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115251_bb0005","series-title":"International Encyclopedia of Public Health","first-page":"509","article-title":"Poliomyelitis","author":"Mach","year":"2017"},{"issue":"19","key":"10.1016\/j.jconrel.2026.115251_bb0010","article-title":"Progress toward polio eradication \u2014 worldwide, January 2020\u2013April 2022","volume":"71","author":"Rachlin","year":"2022","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"34","key":"10.1016\/j.jconrel.2026.115251_bb0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.15585\/mmwr.mm7034a1","article-title":"Progress toward polio eradication - worldwide, January 2019-June 2021","volume":"70","author":"Bigouette","year":"2021","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jconrel.2026.115251_bb0020","author":"World Health Organization"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115251_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/321905","article-title":"Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication","volume":"33","author":"C\u00e1ceres","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"suppl_1","key":"10.1016\/j.jconrel.2026.115251_bb0030","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2026.115251_bb0035","doi-asserted-by":"crossref","first-page":"906","DOI":"10.15585\/mmwr.mm7341a1","article-title":"Update on vaccine-derived poliovirus outbreaks \u2014 worldwide, January 2023\u2013June 2024","volume":"73","author":"Namageyo-Funa","year":"2024","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.jconrel.2026.115251_bb0040","author":"Polio Global Irradication Initiative"},{"issue":"10230","key":"10.1016\/j.jconrel.2026.115251_bb0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(20)30213-0","article-title":"The case for replacing live oral polio vaccine with inactivated vaccine in the Americas","volume":"395","author":"Alfaro-Murillo","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115251_bb0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2026.115251_bb0060","author":"Polio Global Eradication Initiative"},{"key":"10.1016\/j.jconrel.2026.115251_bb0065","article-title":"Microneedle patches for vaccination in developing countries","volume":"240","author":"Arya","year":"2015","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115251_bb0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nm.2182","article-title":"Dissolving polymer microneedle patches for influenza vaccination","volume":"16","author":"Sullivan","year":"2010","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115251_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013460","article-title":"Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model","volume":"5","author":"Corbett","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115251_bb0080","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3109\/10717544.2014.992497","article-title":"DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN","volume":"23","author":"Qiu","year":"2016","journal-title":"Drug Deliv."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115251_bb0085","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.1214449110","article-title":"Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays","volume":"110","author":"Bachy","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/infdis\/jiy139","article-title":"A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques","volume":"218","author":"Joyce","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"16","key":"10.1016\/j.jconrel.2026.115251_bb0095","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","article-title":"Microneedle patches: usability and acceptability for self-vaccination against influenza","volume":"32","author":"Norman","year":"2014","journal-title":"Vaccine"},{"issue":"10095","key":"10.1016\/j.jconrel.2026.115251_bb0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s13063-022-06493-5","volume":"23","author":"Adigweme","year":"2022","journal-title":"Trials"},{"issue":"10439","key":"10.1016\/j.jconrel.2026.115251_bb0110","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","article-title":"A measles and rubella vaccine microneedle patch in The Gambia: a phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial","volume":"403","author":"Adigweme","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115251_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.02.040","article-title":"Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects","volume":"128","author":"Arya","year":"2017","journal-title":"Biomaterials"},{"issue":"37","key":"10.1016\/j.jconrel.2026.115251_bb0120","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1016\/j.vaccine.2017.07.083","article-title":"Acceptability of microneedle-patch vaccines: a qualitative analysis of the opinions of parents","volume":"35","author":"Marshall","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115251_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2018863","article-title":"Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings","volume":"18","author":"Davies","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115251_bb0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40268-016-0144-x","article-title":"Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: the case for further research and development","volume":"16","author":"Adhikari","year":"2016","journal-title":"Drugs R D"},{"issue":"37","key":"10.1016\/j.jconrel.2026.115251_bb0135","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1016\/j.vaccine.2015.02.076","article-title":"An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115251_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169030","article-title":"Potential cost-effectiveness of an influenza vaccination program offering microneedle patch for vaccine delivery in children","volume":"11","author":"Wong","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13346-016-0282-2","article-title":"Long-term stability of influenza vaccine in a dissolving microneedle patch","volume":"7","author":"Mistilis","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115251_bb0150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/acs.biomac.1c01345","article-title":"Dissolving microneedle delivery of a prophylactic HPV vaccine","volume":"23","author":"Ray","year":"2022","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0155","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jps.24283","article-title":"Development of a thermostable microneedle patch for influenza vaccination","volume":"104","author":"Mistilis","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13346-018-00608-9","article-title":"Development of a thermostable microneedle patch for polio vaccination","volume":"9","author":"Kolluru","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0165","article-title":"Mini-review: assessing the potential impact of microneedle technologies on home healthcare applications","volume":"5","author":"McConville","year":"2018","journal-title":"Medicines (Basel)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-022-00443-7","article-title":"Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine","volume":"7","author":"Moon","year":"2022","journal-title":"npj Vaccines"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0175","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.xphs.2018.01.027","article-title":"Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch\u2122 microprojection array","volume":"107","author":"Wan","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"31","key":"10.1016\/j.jconrel.2026.115251_bb0180","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/acs.langmuir.5b01262","article-title":"Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination","volume":"31","author":"van der Maaden","year":"2015","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2026.115251_bb0185","article-title":"Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats","volume":"31","author":"van der Maaden","year":"2014","journal-title":"Pharm. Res."},{"issue":"37","key":"10.1016\/j.jconrel.2026.115251_bb0190","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.vaccine.2015.01.089","article-title":"Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque","volume":"33","author":"Edens","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0195","doi-asserted-by":"crossref","first-page":"12644","DOI":"10.1038\/s41598-017-13011-0","article-title":"High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses","volume":"7","author":"Muller","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115251_bb0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2019.08.039","article-title":"Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies","volume":"311-312","author":"Donadei","year":"2019","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2006.10.017","article-title":"Coated microneedles for transdermal delivery","volume":"117","author":"Gill","year":"2007","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115251_bb0210","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/ac60166a055","article-title":"Saturated salt solutions for static control of relative humidity between 5\u00b0 and 40\u00b0 C","volume":"32","author":"Rockland","year":"1960","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115251_bb0215","first-page":"253","article-title":"Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines","volume":"74","author":"Greenwood","year":"1996","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jconrel.2026.115251_bb0220","author":"World Health Organization"},{"key":"10.1016\/j.jconrel.2026.115251_bb0225","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenver- suche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch. Exp. Pathol. Pharmakol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.6028\/jres.081A.011","article-title":"Humidity fixed points of binary saturated aqueous solutions","volume":"81A","author":"Greenspan","year":"1977","journal-title":"J. Res. Nat. Bureau Standards Sect. A Phys. Chem."},{"key":"10.1016\/j.jconrel.2026.115251_bb0235","series-title":"Epidermal Serine Proteases and Their Inhibitors in Atopic Dermatitis","author":"Meyer-Hoffert","year":"2012"},{"key":"10.1016\/j.jconrel.2026.115251_bb0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2021.07.011","article-title":"Development of a thermostable oxytocin microneedle patch","volume":"337","author":"Gomaa","year":"2021","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115251_bb0245","article-title":"Rational for the intradermal therapy (mesotherapy) in sport medicine: from hypothesis to clinical practice","volume":"54","author":"Mammucari","year":"2019","journal-title":"Res. Inves. Sports Med."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0250","first-page":"75","article-title":"A dangerous gluteal injection","volume":"38","author":"Woo","year":"1986","journal-title":"J. Hong Kong Med. Assoc."},{"issue":"8332","key":"10.1016\/j.jconrel.2026.115251_bb0255","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(83)92679-X","article-title":"Adverse reactions after intramuscular injections","volume":"321","author":"M\u00fcller-Vahl","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0846.2007.00271.x","article-title":"Human skin buffering capacity: an overview","volume":"14","author":"Levin","year":"2008","journal-title":"Skin Res. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0265","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4239\/wjd.v6.i1.125","article-title":"Roles of interstitial fluid pH in diabetes mellitus: glycolysis and mitochondrial function","volume":"6","author":"Marunaka","year":"2015","journal-title":"World J. Diabetes"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115251_bb0270","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.jid.5700288","article-title":"Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome","volume":"126","author":"Hachem","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0275","first-page":"14","article-title":"Application of protease technology in dermatology: rationale for incorporation into skin care and initial observations on formulations designed for skin cleansing, maintenance of hydration and restoration of the epidermal permeability barrier","volume":"6","author":"Rosso","year":"2013","journal-title":"J. Clin. Aesthet. Dematol."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2026.115251_bb0280","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/prca.201300081","article-title":"Proteases and proteomics: cutting to the core of human skin pathologies","volume":"8","author":"de Veer","year":"2014","journal-title":"Proteomics Clin. Appl."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0285","first-page":"14","article-title":"Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier","volume":"6","author":"Del Rosso","year":"2013","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0290","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1074\/jbc.M607567200","article-title":"A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation","volume":"282","author":"Borgono","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2353\/ajpath.2008.070161","article-title":"Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2","volume":"172","author":"Demerjian","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115251_bb0300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2133.1999.03038.x","article-title":"Role of endogenous cathepsin D-like and chymotrypsin-like proteolysis in human epidermal desquamation","volume":"141","author":"Horikoshi","year":"1999","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF01975713","article-title":"Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice","volume":"39","author":"Fujimori","year":"1993","journal-title":"Agents Actions"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115251_bb0310","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0005-2744(76)90337-5","article-title":"The inhibition of human leucocyte elastase and chymotrypsin-like protease by elastatinal and chymostatin","volume":"429","author":"Feinstein","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/biol.1995.0029","article-title":"Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats","volume":"23","author":"Kersten","year":"1995","journal-title":"Biologicals"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0320","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biologicals.2015.07.010","article-title":"Trypsin diminishes the rat potency of polio serotype 3","volume":"43","author":"ten Have","year":"2015","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0325","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/0042-6822(73)90063-9","article-title":"Mechanism of influenza recombination. II. Virus aggregation and its effect on plaque formation by so-called noninfective virus","volume":"56","author":"Hirst","year":"1973","journal-title":"Virology"},{"issue":"20","key":"10.1016\/j.jconrel.2026.115251_bb0330","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1016\/j.cub.2018.08.028","article-title":"Collective infection of cells by viral aggregates promotes early viral proliferation and reveals a cellular-level Allee effect","volume":"28","author":"Andreu-Moreno","year":"2018","journal-title":"Curr. Biol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115251_bb0335","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.progpolymsci.2007.05.008","article-title":"Polymer\u2013drug conjugation, recent achievements and general strategies","volume":"32","author":"Pasut","year":"2007","journal-title":"Prog. Polym. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115251_bb0340","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1021\/bm2007967","article-title":"Noncovalent PEGylation by polyanion complexation as a means to stabilize keratinocyte growth factor-2 (KGF-2)","volume":"12","author":"Khondee","year":"2011","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115251_bb0345","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/bc00028a001","article-title":"Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in-vivo and in-vitro","volume":"5","author":"Kodera","year":"1994","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115251_bb0350","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/jps.22401","article-title":"Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin","volume":"100","author":"Mueller","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115251_bb0355","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/jps.23110","article-title":"Noncovalent PEGylation: different effects of dansyl-, l-tryptophan\u2013, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme","volume":"101","author":"Mueller","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115251_bb0360","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jps.24217","article-title":"Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte","volume":"104","author":"Kurinomaru","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115251_bb0365","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ejpb.2011.06.003","article-title":"Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation","volume":"79","author":"Mueller","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115251_bb0370","author":"U.S. Centers for Disease Control and Prevention"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115251_bb0375","first-page":"529","article-title":"The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomized controlled trial","volume":"215","author":"John","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"32","key":"10.1016\/j.jconrel.2026.115251_bb0380","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2019.03.035","article-title":"Potential use of microarray patches for vaccine delivery in low- and middle- income countries","volume":"37","author":"Peyraud","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115251_bb0385","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14760584.2023.2178421","article-title":"Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays","volume":"22","author":"Zhang","year":"2023","journal-title":"Expert Rev. Vaccines"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:58:26Z","timestamp":1790211506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":76,"alternative-id":["S0168365926006553"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115251","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the weak antibody response to vaccination with inactivated polio virus serotype 3 when delivered by microneedle patch","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115251"}}